drug · antibody drug conjugate
brentuximab vedotin
Phase 2updated 5mo agoby $PFE PFIZER INC🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 2Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 18 investigational indications.
indications
indications
DLBCL
targets
TubulinTumor necrosis factor receptor superfamily member 8
all catalysts(1)
Trials studying brentuximab vedotin
- phase2Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
- phase2Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- phase2BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
- phase2Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
- phase3Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- phase2Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- N/ABrentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
- phase2Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
News(5)
- Pfizer punts Seagen ADC, further muddying value of the $43B buyoutThe co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…biospace · 1mo ago
- Pfizer expands multibillion-dollar cost-cutting planHatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.biopharma_dive · 2mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- UT MD Anderson Shares Latest Research BreakthroughsThe University of Texas MD Anderson Cancer Center released recent oncology research highlights.onclive · 4mo ago
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 5mo ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that